Most Read

A fully human anti-cluster of differentiation (CD3) monoclonal antibody, intranasal foralumab is tailored to modulate the immune system and reduce neuroinflammation, which is a significant factor in the

This marks Epkinly as the first subcutaneously administered T-cell engaging bispecific antibody approved in the country for R/R follicular lymphoma as well as R/R large B-cell lymphomas. The

As part of the agreement terms, UAB has received a non-exclusive licence to leverage the H2L2 Harbour Mice platform of Nona Biosciences for the creation of fully human

Investors for the funding round include Johnson & Johnson Innovation, Deerfield Management, Catalio Capital Management, Braidwell, the Retinal Degeneration Fund, and GV. The company is dedicated to advancing

Following its recent US Food and Drug Administration (FDA) approval, the therapy is now a treatment option for patients aged two years and older with neurofibromatosis type 1

Romvimza is indicated for use in TGCT patients for whom surgery could worsen functional limitations or cause severe morbidity. The approval is based on the results from the

It also focuses on developing the candidate targeting other autoimmune disorders like Lupus Nephritis (LN). The partnership underscores Conduit’s commitment to creating high-quality preclinical data, which will play

As part of this collaboration, Boehringer will utilise ExpressionEdits’ AI-powered platform, Genetic Syntax Engine, designed to boost gene expression without altering the genetic sequence, for the development of

Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and